Aclaris Therapeutics Inc (NASDAQ:ACRS) – Stock analysts at Cantor Fitzgerald raised their FY2018 earnings per share estimates for Aclaris Therapeutics in a research report issued to clients and investors on Wednesday, October 24th. Cantor Fitzgerald analyst L. Chen now anticipates that the biotechnology company will post earnings per share of ($4.55) for the year, up from their previous estimate of ($4.91). Cantor Fitzgerald currently has a “Buy” rating and a $50.00 price target on the stock. Cantor Fitzgerald also issued estimates for Aclaris Therapeutics’ FY2019 earnings at ($3.87) EPS.

A number of other analysts have also recently commented on the company. Zacks Investment Research upgraded Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, September 17th. JMP Securities reduced their price target on Aclaris Therapeutics from $47.00 to $34.00 and set a “buy” rating for the company in a research report on Tuesday, October 16th. Finally, BidaskClub cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $41.60.

Shares of ACRS opened at $12.08 on Monday. Aclaris Therapeutics has a 52 week low of $11.00 and a 52 week high of $26.25.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Friday, August 3rd. The biotechnology company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.04. Aclaris Therapeutics had a negative return on equity of 49.45% and a negative net margin of 1,584.99%. The company had revenue of $3.68 million for the quarter, compared to the consensus estimate of $2.76 million.

Several large investors have recently added to or reduced their stakes in ACRS. FMR LLC grew its position in shares of Aclaris Therapeutics by 31.1% during the second quarter. FMR LLC now owns 3,355,785 shares of the biotechnology company’s stock worth $67,015,000 after purchasing an additional 796,805 shares in the last quarter. BlackRock Inc. grew its position in shares of Aclaris Therapeutics by 9.7% during the second quarter. BlackRock Inc. now owns 2,311,641 shares of the biotechnology company’s stock worth $46,163,000 after purchasing an additional 204,215 shares in the last quarter. Rice Hall James & Associates LLC grew its position in shares of Aclaris Therapeutics by 88.5% during the second quarter. Rice Hall James & Associates LLC now owns 399,342 shares of the biotechnology company’s stock worth $7,975,000 after purchasing an additional 187,545 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Aclaris Therapeutics by 3,694.2% during the first quarter. JPMorgan Chase & Co. now owns 190,281 shares of the biotechnology company’s stock worth $3,333,000 after purchasing an additional 185,266 shares in the last quarter. Finally, C WorldWide Group Holding A S grew its position in shares of Aclaris Therapeutics by 221.9% during the second quarter. C WorldWide Group Holding A S now owns 242,251 shares of the biotechnology company’s stock worth $4,838,000 after purchasing an additional 166,986 shares in the last quarter. Hedge funds and other institutional investors own 99.72% of the company’s stock.

In other Aclaris Therapeutics news, Director Stephen A. Tullman bought 6,250 shares of the business’s stock in a transaction that occurred on Wednesday, August 15th. The stock was purchased at an average price of $15.97 per share, for a total transaction of $99,812.50. Following the completion of the transaction, the director now owns 163,757 shares of the company’s stock, valued at approximately $2,615,199.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Anand Mehra bought 372,093 shares of the business’s stock in a transaction that occurred on Monday, October 22nd. The shares were acquired at an average price of $10.75 per share, with a total value of $3,999,999.75. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 392,043 shares of company stock valued at $4,298,212. Company insiders own 17.00% of the company’s stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Further Reading: How is the S&P 500 index different from the DJIA?

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.